BIOMARCADORES PARA DIAGNÓSTICO DE DEMENCIA

Volver

Resultados 41 resultados LastUpdate Última actualización 24/11/2017 [16:01:00] pdf PDF




Solicitudes publicadas en los últimos 60 días / Applications published in the last 60 days



Página1 de 2 nextPage   Mostrar por página


BLOCKADE OF TIM-1 PATHWAYS AND P-SELECTIN PATHWAYS IN TREATMENT OF NEUROINFLAMMATORY DEGENERATIVE DISEASE

NºPublicación: WO2017197158A1 16/11/2017

Solicitante:
LEUVAS THERAPEUTICS [US]

Resumen de: WO2017197158A1

Methods for treating, preventing and reducing the progression of neurodegenerative and neurological diseases, including, without limitation Alzheimer's disease, are provided. The methods of the invention inhibit one or both of TIM-1 and P-selectin function and reduce leukocyte and platelet cell adhesion, activation and interaction with the vascular endothelium and infiltration of leukocytes into the brain.



traducir


 

METHOD OF DETERMINING AUTOPHAGOSOME FLUX AND USES THEREOF

NºPublicación: WO2017195130A1 16/11/2017

Solicitante:
UNIV STELLENBOSCH [ZA]

Resumen de: WO2017195130A1

A method for measuring autophagosome flux is provided. The autophagosome pool size in a single cell is quantified, where the pool size is the total number of autophagosomes in the cell. Fusion between the autophagosomes and lysosomes in the cell is then inhibited. The autophagosome pool size is quantified over one or more time points after fusion has been inhibited, and the autophagosome flux is calculated as the initial rate of change of the autophagosome pool size at the time point after fusion has been inhibited. The method can be used to determine basal autophagosome flux, whether a cell is diseased or dysfunctional, or to diagnose a subject with a disease, disorder or dysfunction. The transition time, the time required to clear an autophagosome pool, can also be derived from the autophagosome flux. A molecule can also be characterized according to its ability to modulate autophagosome flux in a cell.



traducir


 

BLOCKADE OF TIM-1 PATHWAYS and P-SELECTIN PATHWAYS IN TREATMENT OF NEUROINFLAMMATORY DEGENERATIVE DISEASE

NºPublicación: US2017328919A1 16/11/2017

Solicitante:
LEUVAS THERAPEUTICS [US]

Resumen de: US2017328919A1

Methods for treating, preventing and reducing the progression of neurodegenerative and neurological diseases, including, without limitation Alzheimer's disease, are provided. The methods of the invention inhibit one or both of TIM-1 and P-selectin function and reduce leukocyte and platelet cell adhesion, activation and interaction with the vascular endothelium and infiltration of leukocytes into the brain.



traducir


 

NEUROTOXIC TARGET FOR AMYLOSPHEROID, METHOD AND MATERIAL FOR REDUCING THE NEUROTOXICITY OF AMYLOSPHEROID, AND USE THEREOF

NºPublicación: US2017327536A1 16/11/2017

Solicitante:
TAO HEALTH LIFE PHARMA CO LTD

Resumen de: US2017327536A1

In one or a plurality of embodiments, there is provided a target molecule of amylospheroid, which is expressed in mature neurons and to which the amylospheroid binds to induce death of cells. Further, in one or a plurality of embodiments, there is provided a method and a substance for inhibiting death of mature neurons induced by the amylospheroid. In one aspect, the present disclosure relates to a use of Na−/K+−ATPase α3 as a binding target molecule of amylospheroid. In another aspect, the present disclosure relates to a method for suppressing death of mature neurons induced by the amylospheroid, including inhibiting protein-protein interaction between the amylospheroid and the Na+/K+−ATPase α3, and the like.



traducir


 

FUNCTIONALIZED EYEWEAR DEVICE FOR DETECTING BIOMARKER IN TEARS

NºPublicación: US2017328918A1 16/11/2017

Solicitante:
UNIV OF CENTRAL FLORIDA RESEARCH FOUNDATION INC [US]

Resumen de: US2017328918A1

Disclosed herein is a functionalized eyewear device that is adapted for collecting and analyzing disease biomarkers. Specifically, exemplified is a contact lens that has aptamer molecules associated therewith for binding to a specific biomarker (or biomarkers). The eyewear device is useful for detecting and diagnosing medical conditions.



traducir


 

DIAGNOSTIC MARKER FOR DEMENTIA AND METHOD FOR IDENTIFYING CONTRACTION OF DEMENTIA USING SAID MARKER

NºPublicación: WO2017195778A1 16/11/2017

Solicitante:
HASHIMOTO YASUHIRO [JP]

Resumen de: WO2017195778A1

The present invention addresses the problem of: developing a biomarker which makes it possible to determine the pathology of dementia, or which is used to differentiate dementia, specifically Alzheimer's disease and mild cognitive impairment which could lead to Alzheimer's disease, from other central nervous system diseases; and providing an early diagnostic method and pathology determination method for dementia which use the biomarker. As the Alzheimer's disease diagnostic marker, the present invention uses a transferrin protein which contains a sugar chain having at least one mannose in the non-reducing terminal thereof, or uses a transferrin fragment which contains the sugar chain.



traducir


 

INHIBITION OF TAU-MEDIATED EARLY SYNAPTIC DYSFUNCTION

NºPublicación: WO2017194589A1 16/11/2017

Solicitante:
VIB VZW [BE]
KATHOLIEKE UNIV LEUVEN K U LEUVEN R&D [BE]

Resumen de: WO2017194589A1

The present invention relates to the field of neurodegenerative diseases, including Tauopathies, and the prevention and/or treatment of the early synaptic dysfunction arising in patients thereof. In particular, the present invention relates to screening methods for producing compounds which can prevent the early synaptic dysfunction by inhibiting the reduction of synaptic vesicle mobilization and neurotransmitter release and which can prevent early pathology in varies Tauopathies.



traducir


 

SYNAPTIC PROTEIN BIOMARKERS AND DIFFERENTIAL DIAGNOSIS OF ALZHEIMER'S DISEASE AND OTHER NEURODEGENERATIVE DISORDERS

NºPublicación: WO2017193115A1 09/11/2017

Solicitante:
NANOSOMIX INC [US]

Resumen de: WO2017193115A1

The present invention relates to synaptic protein biomarkers and diagnostic and prognostic methods for Alzheimer's disease and other neurodegenerative disorders. The invention also provides compositions for detecting the synaptic protein biomarkers as well as compositions and methods useful for early diagnosis and/or treatment of Alzheimer's disease and other neurodegenerative disorders. The invention also provides methods for detecting biomarkers in vesicles (e.g., exosomes) isolated from a biological sample.



traducir


 

ASSAY FOR THE DIAGNOSIS OF A NEUROLOGICAL DISEASE

NºPublicación: WO2017190834A1 09/11/2017

Solicitante:
EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG [DE]

Resumen de: WO2017190834A1

The present invention relates to a diagnostically useful carrier comprising a means for capturing Neurogranin, a means for capturing BACE1 and preferably a means for capturing one or more additional biomarkers; a kit comprising the diagnostically useful carrier, optionally further comprising a means for detecting Neurogranin, a means for detecting BACE1 and preferably a means for detecting the one or more additional biomarkers; and a method comprising the steps contacting a sample from a subject with a means for capturing Neurogranin, isolating the means for capturing Neurogranin from the sample and contacting a sample from a subject with a means for capturing BACE1 and isolating the means for capturing BACE1 from the sample. The diagnosis aims to distinguish a neurodegenerative disease, preferably mild Alzheimer's disease, and depression with or without cognitive impairment.



traducir


 

ASSAY FOR THE DIAGNOSIS OF A NEUROLOGICAL DISEASE

NºPublicación: EP3242134A1 08/11/2017

Solicitante:
EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG [DE]
ADX NEUROSCIENCES N V [BE]

Resumen de: EP3242134A1

The present invention relates to a diagnostically useful carrier comprising a means for capturing Neurogranin, a means for capturing BACE1 and preferably a means for capturing one or more additional biomarkers; a kit comprising the diagnostically useful carrier, optionally further comprising a means for detecting Neurogranin, a means for detecting BACE1 and preferably a means for detecting the one or more additional biomarkers; and a method comprising the steps contacting a sample from a subject with a means for capturing Neurogranin, isolating the means for capturing Neurogranin from the sample and contacting a sample from a subject with a means for capturing BACE1 and isolating the means for capturing BACE1 from the sample. The diagnosis aims to distinguish a neurodegenerative disease, preferably mild Alzheimer's disease, and depression with or without cognitive impairment.



traducir


 

TAU IMAGING LIGANDS AND THEIR USES IN THE DIAGNOSIS AND TREATMENT OF TAUOPATHY

NºPublicación: JP2017532288A 02/11/2017

Resumen de: WO2016007414A1

The present invention relates to antibody-based probes (including single domain antibody fragment, scFv molecules, antibodies, antibody fragments, diabodies, and the epitope-binding domains thereof) that are capable of immunospecifically and selectively binding to a phospho-serine-containing epitope of Tau, such as, for example, Tau-phospho-serine 396/404 peptide. Such imaging ligands are useful to detect pathological Tau protein conformer if present in a biological sample, especially in conjunction with the diagnosis of Alzheimer's disease or other tauopathy, and thus provide a diagnostic for Alzheimer's disease and other Tau pathologies. The scFv molecules of the present invention have utility as diagnostic markers for, Alzheimer's disease and related tauopathies and as pharmaceutical compositions for the treatment of such conditions..



traducir


 

Antibody that recognises the T14 peptide of ache

NºPublicación: AU2016240020A1 02/11/2017

Solicitante:
NEURO-BIO LTD

Resumen de: AU2016240020A1

The invention relates to antibodies, and in particular, to antibodies used in the diagnosis and treatment of neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease. The invention extends to methods of diagnosis and therapy of neurodegenerative disorders, and to assays and screens for isolating novel therapeutic compounds for treating such diseases.



traducir


 

IMMUNOGENIC PRODUCTS BASED ON MUTEIN AMYLOID ß (Aß) AMINO ACID SEQUENCES AND USES THEREOF

NºPublicación: JP2017532289A 02/11/2017

Resumen de: WO2016005328A2

The invention relates to immunogenic products based on muteinamyloid β(Aβ) amino acid sequences, in particular to oligomers of Aβ muteins, and to the use of said products in diagnosis, treatment and prevention of conditions such as amyloidoses, and for identifying agents capable of binding to said products.



traducir


 

AMYLOID BINDING AGENTS

NºPublicación: US2017315137A1 02/11/2017

Solicitante:
UNIV CALIFORNIA [US]

Resumen de: US2017315137A1

There are provided compounds and methods for the detection of amyloids and treatment of diseases related to amyloids including Alzheimer's disease and other related amyloid-based neurodegenerative diseases.



traducir


 

METHOD FOR IDENTIFYING INHIBITORS OF PRIMARY NUCLEATION OF AMYLOID-BETA AGGREGATION

NºPublicación: WO2017186203A1 02/11/2017

Solicitante:
FORSCHUNGSZENTRUM J\u00DCLICH GMBH [DE]

Resumen de: WO2017186203A1

The invention relates to a method for identifying inhibitors of the primary nucleation of amyloid-beta aggregation, comprising the following steps: a) A-beta species is provided in a buffer; b) the amyloid-beta aggregation is determined. The method is characterised in that c) two A-beta monomer units with a linker arranged between the A-beta monomers is selected as the A-beta species. Also disclosed are a linker used for that purpose, a kit and the uses thereof.



traducir


 

ANTIBODY HIGHLY SPECIFICALLY RECOGNIZING TURN STRUCTURE AT 22- AND 23-POSITIONS IN AMYLOID BETA

NºPublicación: EP3239295A1 01/11/2017

Solicitante:
UNIV KYOTO [JP]
NAT UNIV CORP CHIBA UNIV [JP]
IMMUNO BIOLOGICAL LAB CO LTD [JP]

Resumen de: EP3239295A1

Provided is an antibody or an immunologically reactive fragment thereof which targets exclusively an A² having a specific turn structure of A² (a toxic conformer of A²). Also provided are a medicinal composition comprising, as an active ingredient, an antibody that specifically recognizes a toxic conformer of A², a kit for assaying a toxic conformer of A², a diagnostic agent for Alzheimer's disease, etc.



traducir


 

METHOD FOR THE BODY FLUID-BASED NEURODEGENERATIVE DISEASE DIAGNOSIS USING HIGH SENSITIVE IMMUNOASSAY OF AGGREGATED PROTEINS BY PHOTOOXIDATION-INDUCED AMPLIFICATION

NºPublicación: KR20170119933A 30/10/2017

Resumen de: US2017307638A1

Disclosed is a method for body fluid-based neurodegenerative disease diagnosis through high-sensitive immunoassay of aggregated proteins by photooxidation-induced amplification. The method according to the present disclosure provides an effect of quantitatively analyzing aggregated proteins in the form of oligomers or monomers which are present in trace amounts in a body fluid and measures normal or abnormal protein aggregation by detecting the aggregated proteins in the form of oligomers or monomers with high sensitivity by reaction of antibody-conjugated enzymes selectively bound to the aggregated proteins with substrates and photooxidation-induced amplification, thereby allowing accurate diagnosis of a neurodegenerative disease.



traducir


 

TAU IMMUNOTHERAPY

NºPublicación: SG10201707855YA 30/10/2017

Solicitante:
PROTHENA BIOSCIENCES LTD [IE]

Resumen de: WO2014165271A2

The invention provides antibodies to tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.



traducir


 

YEAST SCREENS FOR TREATMENT OF HUMAN DISEASE

NºPublicación: US2017306386A1 26/10/2017

Solicitante:
UNIV CHICAGO [US]

Resumen de: US2017306386A1

Screening methods for identifying substances that provide therapeutic value for various diseases associated with protein misfolding are provided. Genetic and chemical screening methods are provided using a yeast system. The methods of the invention provide a rapid and cost-effective method to screen for compounds that prevent protein misfolding and/or protein fibril formation and/or protein aggregation which includes numerous neurodegenerative diseases including Parkinson's disease, Alzheimer's disease, Huntington's disease as well as non-neuronal diseases such as type 2 diabetes.



traducir


 

METHOD FOR THE BODY FLUID-BASED NEURODEGENERATIVE DISEASE DIAGNOSIS USING HIGH SENSITIVE IMMUNOASSAY OF AGGREGATED PROTEINS BY PHOTOOXIDATION-INDUCED AMPLIFICATION

NºPublicación: US2017307638A1 26/10/2017

Solicitante:
KOREA INST SCI & TECH [KR]

Resumen de: US2017307638A1

Disclosed is a method for body fluid-based neurodegenerative disease diagnosis through high-sensitive immunoassay of aggregated proteins by photooxidation-induced amplification. The method according to the present disclosure provides an effect of quantitatively analyzing aggregated proteins in the form of oligomers or monomers which are present in trace amounts in a body fluid and measures normal or abnormal protein aggregation by detecting the aggregated proteins in the form of oligomers or monomers with high sensitivity by reaction of antibody-conjugated enzymes selectively bound to the aggregated proteins with substrates and photooxidation-induced amplification, thereby allowing accurate diagnosis of a neurodegenerative disease.



traducir


 

IMMUNOLOGICAL TARGETING OF PATHOLOGICAL TAU PROTEINS

NºPublicación: JP2017193571A 26/10/2017

Resumen de: US2010316564A1

The present invention relates to methods and compositions for treating, preventing, and diagnosing Alzheimer's Disease or other tauopathies in a subject by administering an immunogenic tau peptide or an antibody recognizing the immunogenic tau epitope under conditions effective to treat, prevent, or diagnose Alzheimer's Disease or other tauopathies. Also disclosed are methods of promoting clearance of aggregates from the brain of the subject and of slowing progression of tau-pathology related behavioral phenotype in a subject.



traducir


 

DIAGNOSTIC METHOD

NºPublicación: US2017307632A1 26/10/2017

Solicitante:
INVEN2 AS [NO]

Resumen de: US2017307632A1

A method of detecting the presence, or monitoring the severity of a condition characterised by the presence of fragments of a marker protein in the brain of a patient. The method comprises: (i) providing a sample comprising macrophages obtained from the patient; and (ii) detecting the presence of the marker protein or fragments thereof in the macrophages. The presence of abnormal levels of the marker protein and/or fragments thereof in the macrophages is indicative of the presence of the condition in the patient. The condition and the marker proteins can be: Alzheimer's Disease and the Abeta peptide, Parkinson's Disease and ubiquitin, Multiple Sclerosis and myelin basic protein, FrontoTemporal Dementia and tau, Amyotrophic Lateral Sclerosis and tau, Parkinson's disease, Lewy Body dementia or Alzheimer's Disease and alpha-synuclein.



traducir


 

ANTIBODIES AGAINST PATHOLOGICAL FORMS OF TDP-43 AND USES THEREOF

NºPublicación: US2017298124A1 19/10/2017

Solicitante:
ACAD SINICA [TW]

Resumen de: US2017298124A1

Disclosed herein are novel pathological form of TDP-43, monoclonal antibodies against such pathological form of TDP-43, and uses thereof. The novel pathological form of TDP-43 is characterized in having a spherical particle size of about 2 to 400 nm in diameter.



traducir


 

BIOMARKER FOR COGNITIVE DYSFUNCTION DISEASES, AND METHOD FOR DETECTION OF COGNITIVE DYSFUNCTION DISEASES USING THE BIOMARKER

NºPublicación: US2017299615A1 19/10/2017

Solicitante:
MCBI INC [JP]

Resumen de: US2017299615A1

The present invention aims to provide methods to detect cognitive impairment including mild cognitive impairment and Alzheimer disease by using a protein or its partial peptide that differs in presence or absence, or in quantity between non-cognitive impairment and patients with cognitive impairment and further aims to present biomarkers comprising said protein and said partial peptide to be used to detect cognitive impairment including Alzheimer disease or mild cognitive impairment. Specifically, a biomarker for diagnosis of psychiatry disease or cognitive impairment comprising protein fragment or peptide of not less than 5 amino acid residues arising from at least one protein or peptide selected from the group of proteins consisting of amino acid sequence expressed by SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, and 25 and selected from the group of partial peptide in these proteins consisting of amino acid sequence expressed by SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, and 27. And further aims to provide diagnostic method using these biomarker.



traducir


 

Alzheimer's Disease

Nº publicación: US2017299614A1 19/10/2017

Solicitante:
THE UNIV OF SUSSEX [GB]

Resumen de: US2017299614A1

Variant forms of Amyloid-beta (Aβ) and kits comprising a variant Aβ are disclosed. The invention also provides uses of these kits and the Aβ variants in Aβ studies, for example in assays and methods for screening novel compounds for use in treating Alzheimer's Disease.


traducir



 

Página1 de 2 nextPage Mostrar por página

Volver